Digital Content 
NEWS #PharmaBuzz
07 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/07/3075821/0/en/European-Commission-approves-TREMFYA-guselkumab-the-first-dual-acting-IL-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderatel.html
25 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/25/3068097/0/en/TREMFYA-guselkumab-receives-European-Commission-approval-for-adults-with-moderately-to-severely-active-ulcerative-colitis-strengthening-Johnson-Johnson-s-leadership-in-inflammatory.html
04 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-significantly-reduce-both-the-signs-and-symptoms-and-the-progression-of-structural-damage-in-adults-living-with-active-psoriatic-arthritis-302420476.html
28 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/28/3051280/0/en/TREMFYA-guselkumab-receives-positive-CHMP-opinion-for-treatment-of-patients-with-moderately-to-severely-active-Crohn-s-Disease.html
21 Mar 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/jj-advances-stelara-succession-scheme-key-fda-nod-tremfya-crohns-disease
28 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/28/3034748/0/en/TREMFYA-guselkumab-receives-positive-CHMP-opinion-for-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis.html
Share 